论文部分内容阅读
目的观察参芍口服液对PCI术后患者血液流变学和血管活性物质的影响。方法 PCI术后患者1 336例,随机分为常规用药组671例和参芍口服液治疗组665例。常规用药组患者采用西药常规治疗,参芍口服液治疗组患者在常规治疗基础上加用参芍口服液10ml,3次/d。对二组患者随访12个月,检测血液流变学各指标值和ET、AngⅡ、TXB2水平。结果用药12个月后,二组患者的血液流变学指标值均较前降低,参芍口服液治疗组的各指标与常规用药组相比降低更显著(均P<0.05)。参芍口服液治疗组ET、AngⅡ、TXB2水平也均较同期常规用药组降低(均P<0.05)。结论参芍口服液能改善PCI术后患者血液流变学指标值和降低血清ET、AngⅡ、TXB2水平。
Objective To observe the effect of Shen-shao Oral Liquid on hemorheology and vasoactive substances in patients after PCI. Methods A total of 1 336 cases of post-PCI patients were randomly divided into conventional treatment group (671 cases) and Shen-shao oral solution-treated group (665 cases). Conventional medication group patients with conventional Western medicine treatment, the Senate oral solution treatment group patients on the basis of conventional treatment plus Shen Shao oral solution 10ml, 3 times / d. The two groups were followed up for 12 months, and the indexes of hemorheology, ET, AngⅡ and TXB2 were detected. Results After 12 months of treatment, the indexes of hemorheology in the two groups were lower than those in the former group, and the indexes in the treatment group were significantly lower than those in the conventional group (all P <0.05). The levels of ET, AngⅡ and TXB2 in the treatment group of Shen-Shao Oral Liquid were also lower than those of the conventional treatment group (all P <0.05). Conclusion Shen-shao oral liquid can improve the hemorrheological indexes and decrease the levels of ET, AngⅡ and TXB2 in patients after PCI.